Need professional-grade analysis? Visit stockanalysis.com
$11.45B
N/A
N/A
N/A
Price Chart
Risk-Adjusted Performance
Also Listed On
Galapagos NV (G1LP34) Price Performance
Galapagos NV (G1LP34) trades on SA in BRL. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at BRL7.91, down 8.02% from the previous close.
Over the past year, G1LP34 has traded between a low of BRL6.87 and a high of BRL10.00. The stock has gained 9.0% over this period. It is currently 20.9% below its 52-week high.
Galapagos NV has a market capitalization of $11.45B.
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Company Info
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- SA
- Currency
- BRL
- Country
- Brazil
Financial Metrics
- Revenue (TTM)
- N/A
- EBITDA
- N/A
- Profit Margin
- N/A
- EPS (TTM)
- N/A
- Book Value
- N/A
Technical Indicators
- 52 Week High
- R$10.00
- 52 Week Low
- N/A
- 50 Day MA
- R$8.78
- 200 Day MA
- R$8.63
- Beta
- N/A
Valuation
- Trailing P/E
- N/A
- Forward P/E
- N/A
- Price/Sales
- N/A
- Price/Book
- N/A
- Enterprise Value
- $11.45B